Exploring different composite definitions of responders to biologic treatment for severe asthma (FULL BEAM Response)
Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults (FULL BEAM Remission)
International research collaboration affirms benefits of biologic therapies across broad severe asthma patient populations worldwide, but also highlights unmet treatment needs: Results from LUMINANT
Cultivating Sustainability: A Day with City Sprouts and the Observational and Pragmatic Research Institute Team (Singapore), May 2, 2024
Ground-breaking new study from ISAR uncovers the power of asthma tests BEC and FeNO to predict effectiveness of biologic therapies in Severe Asthma
New ISAR Research Sheds Light on Asthma Exacerbation Rates: Great Variability Found Across Nations
Thirty-year trends analysis reveals continuous overuse of systemic glucocorticoids to treat patients with asthma in the United Kingdom
Blue reliever inhaler overuse strongly linked with increased asthma attacks: Critical findings revealed in new study from Optimum Patient Care Australia
New evidence reveals the power of biologics to improve severe asthma outcomes in patients with T2 comorbidities
Latest ISAR research reveals the significant impact of pre-existing health on response to treatment with biologics in Severe Asthma
Pioneering Study Reveals No Increased Pneumonia Risk in COPD Patients Using Extrafine Beclometasone Dipropionate in Inhaler Therapy
Observational and Pragmatic Research International Joins the Good Business Charter
LANDMARK STUDY REVEALS ADVERSE OUTCOMES LINKED TO ORAL CORTICOSTEROID USE IN COPD PATIENTS
New inventory of severe asthma registries unlocks potential for global research and best care
A greater number of comorbidities is associated with poorer outcomes among adults with severe asthma
Opportunities to Optimize High-risk COPD Management Persist in US Primary Care
Biologics dramatically reduce steroid requirements and exacerbation rates in severe asthma patients
CONQUEST Shines Spotlight on Opportunities to Enhance Cardiopulmonary Outcomes Among High-risk COPD